Begin clinical studies of the oral combination of lenacapavir and islatravir
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 29 Apr 2021
- Due
- 31 Dec 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“The first clinical studies of the oral combination are expected to begin in the second half of 2021.”
What we found
Evidence strength A What the grades mean
The company initiated the Phase 2 clinical study for the lenacapavir and islatravir combination before the end of 2021, though dosing was subsequently paused in December 2021 due to FDA clinical holds.
-
A Gilead Sciences Inc. 10-K filed 2022-02-23
“In December 2021, Merck announced the decision of the parties to stop all dosing of participants in the Phase 2 clinical study evaluating an oral-weekly combination treatment regimen of lenacapavir and islatravir” ✓ confirmed on the page
Market reaction: the shares moved -1.7% against the S&P 500 over the three sessions around the disclosure (22 Feb 2022 to 25 Feb 2022). What this measures
Checked 2 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Begin
- Deliverable
- clinical studies of oral combination
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
- Depends on
- Partner
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Gilead Sciences Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-GILD-004123 · Corrections policy